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Introduction
Survival of patients with persistent and recurrent cervical
cancer is dismal, and improvement remains a large
unmet need. ADXS11-001 is a live, attenuated, bioengi-
neered Lm-LLO immunotherapy for the treatment of
human papillomavirus (HPV)-associated cancers such as
cervical cancer. ADXS11-001 secretes an HPV-E7 tumor
antigen as a truncated LLO-E7 fusion protein that stimu-
lates antitumor immunity through T cells, while reducing
immune tolerance via T-regulatory and myeloid-derived
suppressor cells. ADXS11-001 has been shown to be safe
and effective in women with recurrent/refractory cervical
cancer. This Phase I study evaluates whether a higher
ADXS11-001 dose than that currently used in Phase II
trials is safe and well tolerated.
Methods
This is a Phase I, dose-escalation, open-label study
(NCT02164461) enrolling women aged ≥18 years with per-
sistent, metastatic, or recurrent squamous/adenocarcinoma
of the cervix and documented disease progression (not
amenable to surgery/standard radiotherapy). Additional
eligibility criteria include: measurable and/or evaluable dis-
ease per Response Evaluation Criteria in Solid Tumors
(RECIST v1.1); Eastern Cooperative Oncology Group
(ECOG) performance status of 0–1; and ≤2 prior treat-
ments for metastatic disease. The primary endpoint is the
safety and tolerability of ADXS11-001; secondary endpoints
include evaluating tumor response and progression-free
survival, and assessing correlative immunologic studies.
Patients will receive ADXS11-001 every 3 weeks during a
12-week treatment cycle. Dose escalation is performed
using the 3+3 design in 2 doses: 5x109 colony-forming
units (CFU; Dose Level 1) and 1x1010 CFU (Dose Level 2).
The recommended Phase II dose will be selected based on
an observed dose-limiting toxicity (DLT) rate of < 33%.
Efficacy is assessed using RECIST v1.1 and immune-related
RECIST. Blood samples will be collected in cycle 1 only
and used for immune monitoring and cytokine/chemokine
analysis.
Results
Enrollment into Dose Level 1 is complete (n=6). Initially
3 patients were enrolled into the first dose cohort;
1 patient experienced grade 3 hypotension as a DLT,
resulting in 3 additional patients being enrolled. The
mean age is 51.3 years, 66.7% (n=4) had ECOG 0 at
baseline, and 83.3% (n=5) patients have squamous
histology. All patients received prior cisplatin-based
concurrent chemoradiation, plus a median of 1.5 (range
0–5) lines of systemic chemotherapy. A total of
16 doses of ADXS11-001 have been safely administered;
accrual for Dose Level 2 is starting. Updated data on the
determination of the maximum tolerated dose and effi-
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